Abaxis Stock – Fundamental Analysis
Not enough price data available yet.
Fundamental Data & Ratios (Balance sheet update: 6/7/2018)
| Balance Sheet | Total Assets | 341,103,000.00 | ROE | – |
| Balance Sheet | Total Equity | 290,693,000.00 | ROA | – |
| Cashflow | Capital Expenditures | -6,046,000.00 | P/FCF | – |
| Cashflow | Free Cash Flow | 37,470,000.00 | – | – |
| Cashflow | Operating Cash Flow | 43,516,000.00 | P/CF | – |
| Income | Earnings per Share (diluted) | 1.17 | Div. Yield | – |
| Income | Net Income | 27,177,000.00 | P/E | – |
| Income | Shares Outstanding | 23,135,000.00 | P/B | – |
| Income | Total Revenue | 244,700,000.00 | P/S | – |
Ratios calculated on: –
Company Description
Abaxis, Inc. (Abaxis) develops, manufactures, markets and sells blood analysis systems for use in the human or veterinary patient-care setting to provide clinicians with rapid blood constituent measurements. The Company's segments include the medical market and the veterinary market. The Company has developed a blood analysis system incorporating all of these criteria into a 5.1 kilogram (11.2 pounds) portable analyzer and a series of menu-specific, multi-test single-use reagent discs. Abaxis markets its blood chemistry analyzers in the medical market and in the veterinary market. The Company markets the blood analysis system in the medical market under the name Piccolo Xpress. It markets the blood analysis system in the veterinary market under the name VetScan VS2.
Additional comparison and history views are available after login.
Finanzoo GmbH assumes no liability for the accuracy of the information provided! All information is provided without guarantee. Sources: www.bundesanzeiger.de, www.sec.gov, www.abaxis.com
All metrics and scores are an automated evaluation and not investment advice or a recommendation to buy or sell. Finanzoo GmbH or its shareholders may themselves hold positions in the securities shown.
Learn more